Charles River Laboratories International, Inc. (CRL) Stock: Price, Forecast & Analyst Target
Charles River Laboratories International, Inc. (CRL) — MoonshotScore 62/100 (Fair band), calculated Oct 5, 2026. Price $310.77 (+7.09%), as of the Oct 5, 2026 trading session; market cap $15.0B. Expected results Nov 4, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 78.11× (market value Oct 5, 2026; cash Jun 27, 2026) · expected results Nov 4, 2026
Charles River Laboratories International, Inc. · CRL · NYSE · Healthcare · Medical - Diagnostics & Research
Research dated 2026-09-13: Charles River Laboratories supplies pharmaceutical and biotechnology companies with research models, outsourced discovery and safety work, manufacturing quality testing, and managed animal facilities rather than developing its own drug portfolio. The case depends on whether recovering demand in Discovery and Safety Assessment and a more profitable Manufacturing mix can outweigh divestiture-related revenue contraction and a heavy debt burden.
Price as of Oct 5, 2026
Key Statistics
MoonshotScore v2 · Charles River Laboratories International (CRL)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, but a fragile balance sheet; the market is already moving on it. Business Quality: Solid; Financial Safety: Fragile; Valuation: Full; Growth Durability: Flat; Momentum: Surging.
- quarterly revenue $1.00B (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 8 of 8
- Altman Z 2.60 · Piotroski F 5
Holding back: balance-sheet strain
Helping: business quality, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 63 | Fair | |
| 62 | Fair | |
| 62 | Fair | |
| 62 | Fair | |
| 62 | Fair | |
| 62 | Fair |
The score was 62 in the stored Oct 4, 2026 snapshot and remains 62 in the current publication computed Oct 5, 2026 (0); the largest pillar moves were Growth Durability +2; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $310.77 | |
| Change on the day | +7.09% | |
| 52-week range | $146.20–$303.31 | |
| Market capitalisation | $15.0B | |
| Shares traded on the day | 1.3M | |
| Beta (volatility vs the S&P 500) | 1.41 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
Our updated guidance assumes an average diluted share count of approximately 48.5 million shares for the full year 2026.
Glenn Coleman · Statement from
We expect the Manufacturing segment to remain a meaningful contributor to margin expansion during the second half of the year with the operating margin approaching 40% with the full benefit being recognized from the CDMO divestiture.
Glenn Coleman · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsOther perspectives
Council score for Charles River Laboratories International (CRL): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
0 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read date unavailable · not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 24, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 24, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 6, 2026, except a card that shows its own read date.
Watch the CRL film — every key number, told as a short cinematic story
~2 min · open the film
What is Charles River Laboratories International (CRL), and what does it report?
Short answer · as of
Research Models and Services provides laboratory animals, engineered models, diagnostics, and facility support.
Research dated 2026-09-13.
Research Models and Services provides laboratory animals, engineered models, diagnostics, and facility support. Discovery and Safety Assessment advances client compounds and biologics through target validation, toxicology, pathology, pharmacology, bioanalysis, metabolism, and pharmacokinetic work, while Manufacturing Solutions provides quality-control testing, biologics testing, and specialized vaccine-production inputs.
Discovery and Safety Assessment contributes most of the segment revenue, so the consolidated figures chiefly reflect client spending on preclinical programs. Revenue measures outsourced research activity, model demand, facility services, and testing volumes—not sales from medicines owned by Charles River.
What do the latest results show for Charles River Laboratories International (CRL)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $1.00B.
Research dated 2026-09-13.
Revenue edged higher from the immediately preceding period but remained below the comparable prior period. Gross profit recovered, operating profit was essentially unchanged, and the statutory net loss narrowed sharply.
Revenue and the earnings measure used for estimate comparisons have exceeded expectations throughout the displayed earnings history, although recent statutory results have included losses. Management attributes the expected reported revenue contraction primarily to completed divestitures and says underlying growth should benefit from improving Discovery and Safety Assessment demand and a rebound in Biologics Testing; it also expects the CDMO divestiture to improve Manufacturing margins while higher performance-based compensation raises corporate costs.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $1.00B Jun 27, 2026
- Latest quarter · SG&A
- $228.90M Jun 27, 2026
- Latest quarter · FMP standardized operating result
- $119.89M Jun 27, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 27, 2026 | $1.00B | Not available | $228.90M | $119.89M |
| Mar 28, 2026 | $995.83M | Not available | $159.42M | $119.90M |
| Dec 27, 2025 | $994.23M | Not available | $187.63M | $120.22M |
| Sep 27, 2025 | $1.00B | Not available | $177.59M | $133.80M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $1.00B Aug 5, 2026
- Latest report · revenue estimate
- $977.20M Aug 5, 2026
- Latest report · revenue vs estimate
- Above estimate Aug 5, 2026
- Latest report · EPS vs estimate
- Above estimate Aug 5, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 5, 2026 | $1.00B | $977.20M | $3.0200 | $2.7400 |
| May 7, 2026 | $995.83M | $977.46M | $2.0600 | $1.9600 |
| Feb 18, 2026 | $994.23M | $987.02M | $2.3900 | $2.3300 |
| Nov 5, 2025 | $1.00B | $987.20M | $2.4300 | $2.3200 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $1.00B | -$1M | -$0.03 (diluted) |
| Q1 FY2026 | $996M | -$15M | -$0.30 (diluted) |
| Q4 FY2025 | $994M | -$277M | -$5.62 (diluted) |
| Q3 FY2025 | $1.00B | $54M | $1.10 (diluted) |
What are the financial strengths and risks for Charles River Laboratories International (CRL)?
Short answer
Cash and short-term investments were $192.03M at the Jun 27, 2026 balance-sheet date. Operating cash flow was $179.73M for the quarter ended Jun 27, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Operating cash flow remained positive throughout the displayed period and strengthened most recently, while lower capital spending improved the cash left after investment in the business. Cash and short-term investments moved only modestly across the reported window, and long-term investments provide an additional balance beyond that immediately available pool.
Even after including those investments, the balance is far below total debt. Working-capital ratios sit above parity, but leverage is meaningful and trailing net returns are negative; renewed weakness in client preclinical spending would pressure the dominant Discovery and Safety Assessment segment while leaving less financial flexibility.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $179.73M Jun 27, 2026
- Previous quarter · operating cash flow
- $41.08M Mar 28, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 27, 2026 | $179.73M | −$31.10M |
| Mar 28, 2026 | $41.08M | −$55.91M |
| Dec 27, 2025 | $147.52M | −$88.95M |
| Sep 27, 2025 | $213.83M | −$35.58M |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Charles River Laboratories International (CRL)?
Short answer · as of
The next earnings report is expected on Nov 4, 2026.
Research dated 2026-09-13.
At the scheduled earnings release, watch the split between divestiture-driven reported contraction and underlying activity. Improving Discovery and Safety Assessment demand, faster Biologics Testing growth, and a richer Manufacturing margin would support management’s account; broader weakness or rising corporate costs that absorb those benefits would challenge it.
Consensus expectations embed near-term revenue below the latest annual result followed by expansion in later forecast periods. Cash conversion therefore matters alongside earnings comparisons: continued operating cash generation would help contain balance-sheet risk, while deterioration would make the debt load more consequential.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
Our updated guidance assumes an average diluted share count of approximately 48.5 million shares for the full year 2026.
Glenn Coleman ·
We expect the Manufacturing segment to remain a meaningful contributor to margin expansion during the second half of the year with the operating margin approaching 40% with the full benefit being recognized from the CDMO divestiture.
Glenn Coleman ·
Based upon our second quarter results and updated forecast, which also encompasses higher performance-based compensation, we now expect unallocated corporate costs of approximately 6.0% of revenue for the full year compared to our prior outlook of approximately 5.5%.
Glenn Coleman ·
For the third quarter, revenue is expected to decline approximately 4% to 6% on a reported basis, primarily driven by the impact of the completed divestitures. We expect organic revenue growth of approximately 1% to 3% year-over-year, reflecting improving demand trends in the DSA segment and an expected rebound in Biologics Testing growth rate, which will drive higher manufacturing revenue growth.
Glenn Coleman ·
How does Charles River Laboratories International compare with its peers?
Short answer
Charles River Laboratories International's score ranks 11th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Charles River is not primarily a patient-diagnostics company. It sells research inputs and outsourced scientific work used during drug discovery, non-clinical development, safety evaluation, and manufacturing quality control.
Its unusual breadth runs from breeding research models and operating client vivariums to evaluating drug candidates and testing biologics. A CRO concentrated on study execution lacks that same connection to laboratory inputs and managed facilities, yet Charles River’s revenue concentration still makes preclinical development demand the dominant economic exposure.
| Company | Price | Market value | Score |
|---|---|---|---|
| $317.11 Oct 5, 2026 | $12.5B | 95 5-pillar Oct 5, 2026 | |
| $518.39 Oct 2, 2026 | $40.9B | 93 5-pillar Oct 5, 2026 | |
| $620.51 Oct 5, 2026 | $17.3B | 92 5-pillar Oct 5, 2026 | |
| $45.79 Oct 5, 2026 | $9.44B | 86 5-pillar Oct 5, 2026 | |
| $1541.63 Oct 5, 2026 | $31.2B | 82 5-pillar Oct 5, 2026 | |
| $178.72 Oct 5, 2026 | $11.5B | 75 5-pillar Oct 5, 2026 | |
| $232.20 Oct 5, 2026 | $25.6B | 74 5-pillar Oct 5, 2026 | |
| $157.36 Oct 5, 2026 | $17.6B | 71 5-pillar Oct 5, 2026 | |
| $308.65 Oct 5, 2026 | $25.3B | 71 5-pillar Oct 5, 2026 | |
| $168.33 Oct 5, 2026 | $12.9B | 70 5-pillar Oct 5, 2026 | |
| Charles River Laboratories International (CRL) — this page | $310.77 | $15.0B | 62 |
| $24.22 Oct 5, 2026 | $12.5B | 54 5-pillar Oct 5, 2026 | |
| $205.00 Oct 5, 2026 | $12.8B | 36 5-pillar Oct 5, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $219.00 – $357.00
- Consensus target
- $305.50
- Median target
- $321.00
Consensus record · Captured .
Measured against a quoted price of $310.77 (as of Oct 5, 2026).
Insider activity
Form 4 records via FMP · Of the newest 15 records, those within the last 180 days, newest dated Sep 30, 2026
- Transactions
- 15
- Identified insiders
- 5
- Purchases
- 1
- Sales
- 4
- Other transactions
- 10
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Reporting holders
- 584 Period end Jun 30, 2026
- Previous quarter · holders
- 574 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Fmr LLC | 4,239,752 |
| Blackrock, INC. | 3,798,560 |
| Vanguard Capital Management LLC | 3,149,288 |
| Invesco Ltd. | 2,984,785 |
| Harris Associates L P | 2,241,144 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Charles River Laboratories International (CRL)?
Charles River Laboratories International Healthcare Stock: Key Questions Answered
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What does Charles River’s Discovery and Safety Assessment segment actually sell?
It sells outsourced work that helps clients identify and validate therapeutic targets, evaluate compounds and antibodies, and prepare candidates for safety assessment through toxicology, pathology, pharmacology, bioanalysis, metabolism, and pharmacokinetic services.
Why can the CDMO divestiture shrink Charles River’s revenue while lifting Manufacturing Solutions margins?
Removing the divested operation reduces reported revenue, while management expects the remaining Manufacturing mix to carry stronger margins once the divestiture effect is fully reflected. The improvement still has to overcome higher expected corporate costs.
How do Charles River’s research models and contract vivariums reinforce each other?
Charles River supplies laboratory animals and related diagnostics while also managing animal housing, care, and research facilities for biopharmaceutical clients. That places it inside both the research input purchase and the ongoing operation of the client’s preclinical environment.
Why can Charles River beat earnings estimates while reporting a statutory loss?
The estimate-comparison earnings series and income-statement diluted earnings are different presentations. The latest comparison shows an earnings beat while the statutory line remained slightly negative, so an estimate beat does not by itself establish positive net income.
What is the CRL stock price today?
The last price recorded on this page for Charles River Laboratories International, Inc. (CRL) is $310.77, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the CRL price target?
The analyst consensus price target for Charles River Laboratories International, Inc. (CRL) is $305.50 (range $219.00 to $357.00, median $321.00), per FMP data captured Oct 5, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (76 figures)
The 76 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Glenn Coleman (Aug 5, 2026): Our updated guidance assumes an average diluted share count of approximately 48.5 million shares for the full year 2026. Glenn Coleman (Aug 5, 2026): We expect the Manufacturing segment to remain a meaningful contributor to margin expansion during the second half of the year with the operating margin approaching 40% with the full benefit being recognized from the CDMO divestiture. Glenn Coleman (Aug 5, 2026): Based upon our second quarter results and updated forecast, which also encompasses higher performance-based compensation, we now expect unallocated corporate costs of approximately 6.0% of revenue for the full year compared to our prior outlook of approximately 5.5%. Glenn Coleman (Aug 5, 2026): For the third quarter, revenue is expected to decline approximately 4% to 6% on a reported basis, primarily driven by the impact of the completed divestitures. We expect organic revenue growth of approximately 1% to 3% year-over-year, reflecting improving demand trends in the DSA segment and an expected rebound in Biologics Testing growth rate, which will drive higher manufacturing revenue growth. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | Wilmington, MA | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "251 Ballardvale Street, Wilmington, MA, 01887, US". |
FMP — 67 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Nov 4, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $310.77 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T20:00:02.000Z. | |
px.change | Change on the day | +7.09% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $15.0B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-05. FMP quote timestamp: 2026-10-05T20:00:02.000Z. Captured from FMP at 2026-10-06T03:33:35.337Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$20.58 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $1.00B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $146.20–$303.31 | FMP | Financial Modeling Prep (FMP) quote | |
px.volume | Shares traded on the day | 1.3M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 1.41 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Birgit Girshick | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 19,000 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $3.54B, net result $390.98M; FY2022 revenue $3.98B, net result $486.23M; FY2023 revenue $4.13B, net result $474.62M; FY2024 revenue $4.05B, net result $10.30M; FY2025 revenue $4.02B, net result −$144.34M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | Manufacturing Support $766.41M · Research Models and Services $846.08M · Discovery and Safety Assessment $2.40B | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.gross_margin | Gross margin (trailing twelve months) | 32.2% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-27.revenue_k | Revenue — period end 2026-06-27 | $1.00B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-27.sga_k | SG&A — period end 2026-06-27 | $228.90M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-27.operating_result_k | FMP standardized operating result — period end 2026-06-27 | $119.89M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-28.revenue_k | Revenue — period end 2026-03-28 | $995.83M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-28.sga_k | SG&A — period end 2026-03-28 | $159.42M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-28.operating_result_k | FMP standardized operating result — period end 2026-03-28 | $119.90M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-27.revenue_k | Revenue — period end 2025-12-27 | $994.23M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-27.sga_k | SG&A — period end 2025-12-27 | $187.63M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-27.operating_result_k | FMP standardized operating result — period end 2025-12-27 | $120.22M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-27.revenue_k | Revenue — period end 2025-09-27 | $1.00B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-27.sga_k | SG&A — period end 2025-09-27 | $177.59M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-27.operating_result_k | FMP standardized operating result — period end 2025-09-27 | $133.80M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-08-05.revenue_actual | Revenue · reported — report date 2026-08-05 | $1.00B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-05.revenue_estimated | Revenue · estimate — report date 2026-08-05 | $977.20M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-05.eps_actual | EPS · reported — report date 2026-08-05 | $3.0200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-05.eps_estimated | EPS · estimate — report date 2026-08-05 | $2.7400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.revenue_actual | Revenue · reported — report date 2026-05-07 | $995.83M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.revenue_estimated | Revenue · estimate — report date 2026-05-07 | $977.46M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.eps_actual | EPS · reported — report date 2026-05-07 | $2.0600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.eps_estimated | EPS · estimate — report date 2026-05-07 | $1.9600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-18.revenue_actual | Revenue · reported — report date 2026-02-18 | $994.23M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-18.revenue_estimated | Revenue · estimate — report date 2026-02-18 | $987.02M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-18.eps_actual | EPS · reported — report date 2026-02-18 | $2.3900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-18.eps_estimated | EPS · estimate — report date 2026-02-18 | $2.3300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-05.revenue_actual | Revenue · reported — report date 2025-11-05 | $1.00B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-05.revenue_estimated | Revenue · estimate — report date 2025-11-05 | $987.20M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-05.eps_actual | EPS · reported — report date 2025-11-05 | $2.4300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-05.eps_estimated | EPS · estimate — report date 2025-11-05 | $2.3200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $192.03M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | $179.73M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-27. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $206.47M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $3.03B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 4.95× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-27.operating_cash_flow_m | Operating cash flow — period end 2026-06-27 | $179.73M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-28.operating_cash_flow_m | Operating cash flow — period end 2026-03-28 | $41.08M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-27.capex_m | Capital expenditure (reported) — period end 2026-06-27 | −$31.10M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-28.capex_m | Capital expenditure (reported) — period end 2026-03-28 | −$55.91M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-27.operating_cash_flow_m | Operating cash flow — period end 2025-12-27 | $147.52M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-27.capex_m | Capital expenditure (reported) — period end 2025-12-27 | −$88.95M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-27.operating_cash_flow_m | Operating cash flow — period end 2025-09-27 | $213.83M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-27.capex_m | Capital expenditure (reported) — period end 2025-09-27 | −$35.58M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $219.00 – $357.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $305.50 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $321.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 15 transactions · 1 purchases, 4 sales, 10 other transactions · 5 identified insiders · of the newest 15 records, those within the last 180 days, newest dated Sep 30, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.holders | Reporting holders | 584 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 574 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Fmr LLC — shares in provider snapshot | 4,239,752 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Blackrock, INC. — shares in provider snapshot | 3,798,560 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Vanguard Capital Management LLC — shares in provider snapshot | 3,149,288 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Invesco Ltd. — shares in provider snapshot | 2,984,785 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Harris Associates L P — shares in provider snapshot | 2,241,144 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 2 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 8 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-01 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 2.60 · Piotroski F 5 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 · Expired observation |
COMPUTED — 3 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 78.11× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $192.03M at Jun 27, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-05. Balance-sheet reference date: 2026-06-27. The inputs do not establish a single common source date for this ratio. |
earn.history.depth.2026-08-05.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($1.00B) with the recorded estimate ($977.20M) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-05.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($3.0200) with the recorded estimate ($2.7400) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 62 of 100 · Fair · pillars 70 / 17 / 42 / 48 / 93 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 62 (stored snapshot Oct 4, 2026) → 62 (current publication computed Oct 5, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-27. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-27.revenue_k,fin.q_table.depth.2026-06-27.sga_k,fin.q_table.depth.2026-06-27.operating_result_k,fin.q_table.depth.2026-03-28.revenue_k,fin.q_table.depth.2026-03-28.sga_k,fin.q_table.depth.2026-03-28.operating_result_k,fin.q_table.depth.2025-12-27.revenue_k,fin.q_table.depth.2025-12-27.sga_k,fin.q_table.depth.2025-12-27.operating_result_k,fin.q_table.depth.2025-09-27.revenue_k,fin.q_table.depth.2025-09-27.sga_k,fin.q_table.depth.2025-09-27.operating_result_k. - Earnings-history note. Source series as of 2026-08-05. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-05.revenue_actual,earn.history.depth.2026-08-05.revenue_estimated,earn.history.depth.2026-08-05.revenue_actual.comparison,earn.history.depth.2026-08-05.eps_actual.comparison,earn.history.depth.2026-08-05.eps_actual,earn.history.depth.2026-08-05.eps_estimated,earn.history.depth.2026-05-07.revenue_actual,earn.history.depth.2026-05-07.revenue_estimated,earn.history.depth.2026-05-07.eps_actual,earn.history.depth.2026-05-07.eps_estimated,earn.history.depth.2026-02-18.revenue_actual,earn.history.depth.2026-02-18.revenue_estimated,earn.history.depth.2026-02-18.eps_actual,earn.history.depth.2026-02-18.eps_estimated,earn.history.depth.2025-11-05.revenue_actual,earn.history.depth.2025-11-05.revenue_estimated,earn.history.depth.2025-11-05.eps_actual,earn.history.depth.2025-11-05.eps_estimated. - Cash-flow note. Source series as of 2026-06-27. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-27.operating_cash_flow_m,fin.opcf.depth.2026-03-28.operating_cash_flow_m,fin.opcf.depth.2026-06-27.capex_m,fin.opcf.depth.2026-03-28.capex_m,fin.opcf.depth.2025-12-27.operating_cash_flow_m,fin.opcf.depth.2025-12-27.capex_m,fin.opcf.depth.2025-09-27.operating_cash_flow_m,fin.opcf.depth.2025-09-27.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Legal name | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Our market-data provider lists the name as "Charles River Laboratories International, Inc."; the filer's own record is used here. | 2026-02-18 | OFFICIAL | SEC EDGAR — 10-K filed 2026-02-18 |
| Business description | Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Revenue by segment | Manufacturing Support: $766.41M; Research Models and Services: $846.08M; Discovery and Safety Assessment: $2.40B | 2025-12-27 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Management outlook — dated call excerpts | Captured record · 4 entries
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-08-05 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
| Cash, investments and debt | Total debt: $3.03B; Liquidity basis: cash and short-term investments; Total liabilities: $4.69B; Cash and short-term investments: $192.03M; Cash and investments: $398.50M; Long-term investments: $206.47M; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-27 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-27 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-27 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-08-05 | FMP | Financial Modeling Prep (FMP) earnings |
| Most recent periodic reports | 2026-08-05 | OFFICIAL | SEC EDGAR filer submissions | |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-27 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $398.50M; Cash and short-term investments: $192.00M; Long-term investments: $206.50M; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-27 | COMPUTED | Computed from the balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-27 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash decline over the reported window | To: 2026-06-27; From: 2024-09-28; Periods: 7; Cash basis: cash and short-term investments; Closing balance: $192.00M; Decline: $18.10M; Opening balance: $210.20M; Average change per period: $2.60M Change in cash, cash equivalents and short-term investments between the 2024-09-28 and 2026-06-27 balance sheets.; This is a balance change, not operating burn: financing and investing move it too.; Averaged over 7 reporting periods of unequal length. | 2026-06-27 | COMPUTED | Computed from reported balances |
| Cash against market value | As of: 2026-06-27; Cash basis: cash and short-term investments; Net cash: -$2.84B; Total debt: $3.03B; Cash and investments: $192.00M Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-27 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Trailing twelve-month ratio set | Quick ratio: 1.04; Current ratio: 1.35; Debt to equity: 1.07; Net margin: -6%; Gross margin: 32.2%; Operating margin: 12.3%; Return on assets: -3.2%; Return on equity: -7.7% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Next earnings report | Date: 2026-11-04; EPS estimate: $2.96 per share; Revenue estimate: $958.47M The date is our provider's estimate until the company confirms it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-13 | FMP | Financial Modeling Prep (FMP) analyst estimates |
| Sector / industry (provider taxonomy) | Healthcare / Medical - Diagnostics & Research The company's SEC filings classify it under SIC 8731 — Services-Commercial Physical & Biological Research. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
Data provided for informational purposes only.